Log in to your Inderes Free account to see all free content on this page.
Brain+
0.035
DKK
-1.68 %
Less than 1K followers
BRAINP
First North Denmark
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-1.68%
+5.65%
-24.54%
-20.29%
-11.52%
-49.57%
-96.38%
-
-97.43%
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.
Read moreMarket cap
33.92M DKK
Turnover
4.72K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
29.4.
2025
Annual report '24
29.5.
2025
General meeting '25
28.8.
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group
Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio